Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Wilhelmus J A Kersten"'
The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL
Autor:
Annette V. Jacobsen, Catia L. Pierotti, Kym N. Lowes, Amanda E. Au, Ying Zhang, Nima Etemadi, Cheree Fitzgibbon, Wilhelmus J. A. Kersten, André L. Samson, Mark F. van Delft, David C. S. Huang, Hélène Jousset Sabroux, Guillaume Lessene, John Silke, James M. Murphy
Publikováno v:
Cell Death and Disease, Vol 13, Iss 4, Pp 1-13 (2022)
Abstract Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the upstream kinases, receptor interacting p
Externí odkaz:
https://doaj.org/article/f547bcb22fb646c5bc4448de09ec5253
Autor:
Catia L. Pierotti, Annette V. Jacobsen, Christoph Grohmann, Ruby K. Dempsey, Nima Etemadi, Joanne M. Hildebrand, Cheree Fitzgibbon, Samuel N. Young, Katherine A. Davies, Wilhelmus J. A. Kersten, John Silke, Kym N. Lowes, Hélène Jousset Sabroux, David C. S. Huang, Mark F. van Delft, James M. Murphy, Guillaume Lessene
Publikováno v:
Biochemical Journal. 480:665-684
Necroptosis is a mode of programmed, lytic cell death that is executed by the mixed lineage kinase domain-like (MLKL) pseudokinase following activation by the upstream kinases, receptor-interacting serine/threonine protein kinase (RIPK)-1 and RIPK3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1e367c56072dc0c1f4750c019048c86
https://doi.org/10.1042/bcj20230035
https://doi.org/10.1042/bcj20230035
Autor:
Emma J. Petrie, Jarrod J. Sandow, Annette V. Jacobsen, Brian J. Smith, Michael D. W. Griffin, Isabelle S. Lucet, Weiwen Dai, Samuel N. Young, Maria C. Tanzer, Ahmad Wardak, Lung-Yu Liang, Angus D. Cowan, Joanne M. Hildebrand, Wilhelmus J. A. Kersten, Guillaume Lessene, John Silke, Peter E. Czabotar, Andrew I. Webb, James M. Murphy
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-15 (2018)
RIPK3-mediated phosphorylation of the mixed lineage kinase domain-like (MLKL) pseudokinase is thought to be the trigger for MLKL activation during necroptotic signaling. Here the authors provide evidence that the transition of human MLKL from a monom
Externí odkaz:
https://doaj.org/article/15857781bc14483aa896810340066149
Autor:
Isabelle S Lucet, James M. Murphy, Wil I. L. Lehmann, Annette V. Jacobsen, Diane Coursier, Guillaume Lessene, Cheree Fitzgibbon, Lung-Yu Liang, Kym N Lowes, Wilhelmus J A Kersten, Najoua Lalaoui, Jarrod J. Sandow, Gerard Manning, Andre L. Samson, Helene Jousset Sabroux, Emma J. Petrie, Samuel N. Young, Andrew I. Webb, Amanda E. Au
Publikováno v:
Cell Reports, Vol 28, Iss 13, Pp 3309-3319.e5 (2019)
Summary: Necroptotic cell death has been implicated in many human pathologies and is thought to have evolved as an innate immunity mechanism. The pathway relies on two key effectors: the kinase receptor-interacting protein kinase 3 (RIPK3) and the te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c4e9498e391105dda8e088d1d35b5bf
http://www.sciencedirect.com/science/article/pii/S2211124719311039
http://www.sciencedirect.com/science/article/pii/S2211124719311039
Autor:
James M. Murphy, Joanne M Hildebrand, Maria C. Tanzer, John Silke, Jean-Marc Garnier, Cheree Fitzgibbon, Isabelle S Lucet, Pooja Sharma, Wilhelmus J A Kersten, Lung-Yu Liang, Meng-Xiao Luo, Catia L Pierotti, Anne Hempel, Guillaume Lessene, David C.S. Huang, Mark F. van Delft, Peter E. Czabotar, Angus D. Cowan, Sarah E Garnish, Annette V. Jacobsen, Ueli Nachbur
Publikováno v:
ACS chemical biology. 15(10)
Necroptosis is an inflammatory form of programmed cell death that has been implicated in various human diseases. Compound 2 is a more potent analogue of the published compound 1 and inhibits necroptosis in human and murine cells at nanomolar concentr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfa4eb4ea602afb2a9e9bc7dc5e391e0
https://pubmed.ncbi.nlm.nih.gov/32902249
https://pubmed.ncbi.nlm.nih.gov/32902249
The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL
Autor:
Annette V, Jacobsen, Catia L, Pierotti, Kym N, Lowes, Amanda E, Au, Ying, Zhang, Nima, Etemadi, Cheree, Fitzgibbon, Wilhelmus J A, Kersten, André L, Samson, Mark F, van Delft, David C S, Huang, Hélène Jousset, Sabroux, Guillaume, Lessene, John, Silke, James M, Murphy
Publikováno v:
Cell deathdisease. 13(4)
Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the upstream kinases, receptor interacting protein ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c78db6694b72bc48f1f34640362a5488
https://pubmed.ncbi.nlm.nih.gov/35365636
https://pubmed.ncbi.nlm.nih.gov/35365636
Autor:
Michael D. W. Griffin, Guillaume Lessene, Joanne M Hildebrand, Isabelle S Lucet, Brian J. Smith, Samuel N. Young, Wilhelmus J A Kersten, Maria C. Tanzer, Annette V. Jacobsen, John Silke, Peter E. Czabotar, Angus D. Cowan, James M. Murphy, Emma J. Petrie, Jarrod J. Sandow, Ahmad Wardak, Lung-Yu Liang, Weiwen Dai, Andrew I. Webb
Publikováno v:
Nature Communications
Nature Communications, Vol 9, Iss 1, Pp 1-15 (2018)
Nature Communications, Vol 9, Iss 1, Pp 1-15 (2018)
Necroptotic cell death is mediated by the most terminal known effector of the pathway, MLKL. Precisely how phosphorylation of the MLKL pseudokinase domain activation loop by the upstream kinase, RIPK3, induces unmasking of the N-terminal executioner
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0905eae8c46de08ff990f741c301aced
http://europepmc.org/articles/PMC6013482
http://europepmc.org/articles/PMC6013482
Autor:
Ian P. Street, Erinna F. Lee, Brad E. Sleebs, Andrew H. Wei, Rebecca M Moss, Peter M. Colman, Effie Hatzis, Guillaume Lessene, John P Parisot, Jerry M. Adams, David C.S. Huang, Mark F. van Delft, Keith G. Watson, Wilhelmus J A Kersten, Sanjitha Kulasegaram, Hong Yang, Peter E. Czabotar, Jonathan B. Baell, George Nikolakopoulos, Kym N Lowes, Lin Chen, W. Douglas Fairlie
Publikováno v:
Journal of Medicinal Chemistry. 56:5514-5540
Developing potent molecules that inhibit Bcl-2 family mediated apoptosis affords opportunities to treat cancers via reactivation of the cell death machinery. We describe the hit-to-lead development of selective Bcl-XL inhibitors originating from a hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677936ab828328fb7f66e0e2d4cd230e
https://doi.org/10.1021/jm400556w
https://doi.org/10.1021/jm400556w
Autor:
Luxi Zhang, Scott Raymond Walker, Wilhelmus J A Kersten, Ian P. Street, Lynda Allan, Hendrik Falk, Patricia A. Pilling, Thomas S. Peat, I. Holmes, Theresa Connor, John D. Bentley, Naveid A. Ali, Jianmin Wu, Roger J. Daly, Melanie de Silva, Falko Hochgräfe, Emily S. Humphrey, Brendon J. Monahan
Publikováno v:
Journal of Proteome Research. 12:3104-3116
Kinase enrichment utilizing broad-spectrum kinase inhibitors enables the identification of large proportions of the expressed kinome by mass spectrometry. However, the existing inhibitors are still inadequate in covering the entire kinome. Here, we i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::657a2fb0f14ff05f0d898e1a11627b7a
https://doi.org/10.1021/pr3008495
https://doi.org/10.1021/pr3008495
Autor:
Brad E. Sleebs, Philippe Bergeron, Jonathan B. Baell, Wilhelmus J A Kersten, Zhi-Fu Tao, Lisa A. Hasvold, Paul Gibbons, Keith G. Watson, Michael F. T. Koehler, Wayne J. Fairbrother, Carl S. Rye, Sanjitha Kulasegaram, Guillaume Lessene, Chinh T. Bui, Brian J. Smith, Peter M. Colman, Le Wang, Edna F. Choo, Danette Dudley, Steven W. Elmore, David C.S. Huang, Chudi Ndubaku, Kevin Lau, Peter E. Czabotar, John A. Flygare, Andrew J. Souers, George Nikolakopoulos
Publikováno v:
ACS medicinal chemistry letters. 5(6)
Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc09ab7a628075f7e5221d29bcc56d72
https://pubmed.ncbi.nlm.nih.gov/24944740
https://pubmed.ncbi.nlm.nih.gov/24944740